Aubrey Capital Management Ltd lifted its position in shares of Zoetis Inc (NYSE:ZTS) by 19.4% during the 1st quarter, HoldingsChannel reports. The firm owned 43,000 shares of the company’s stock after acquiring an additional 7,000 shares during the period. Zoetis accounts for about 2.1% of Aubrey Capital Management Ltd’s investment portfolio, making the stock its 19th biggest holding. Aubrey Capital Management Ltd’s holdings in Zoetis were worth $4,329,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in Zoetis in the first quarter worth $25,000. Glassman Wealth Services boosted its holdings in Zoetis by 306.5% in the first quarter. Glassman Wealth Services now owns 252 shares of the company’s stock worth $25,000 after acquiring an additional 190 shares in the last quarter. Berman Capital Advisors LLC bought a new stake in Zoetis in the fourth quarter worth $26,000. Private Ocean LLC bought a new stake in Zoetis in the first quarter worth $27,000. Finally, Athena Capital Advisors LLC bought a new stake in Zoetis in the fourth quarter worth $29,000. Institutional investors own 90.30% of the company’s stock.
In other news, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $101.89, for a total value of $203,780.00. Following the completion of the transaction, the insider now owns 30,727 shares in the company, valued at $3,130,774.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Roman Trawicki sold 4,700 shares of the business’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $109.00, for a total value of $512,300.00. Following the completion of the transaction, the insider now owns 2,199 shares of the company’s stock, valued at approximately $239,691. The disclosure for this sale can be found here. Insiders sold 76,716 shares of company stock valued at $7,805,856 in the last 90 days. Company insiders own 0.29% of the company’s stock.
ZTS stock opened at $110.16 on Wednesday. Zoetis Inc has a 1-year low of $78.90 and a 1-year high of $111.66. The company has a debt-to-equity ratio of 2.84, a current ratio of 4.05 and a quick ratio of 2.79. The firm has a market capitalization of $52.68 billion, a PE ratio of 35.19, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s revenue was up 6.5% on a year-over-year basis. As a group, research analysts anticipate that Zoetis Inc will post 3.48 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be paid a $0.164 dividend. This represents a $0.66 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 21.09%.
Several research firms have commented on ZTS. Barclays began coverage on Zoetis in a report on Tuesday. They issued an “overweight” rating and a $120.00 target price on the stock. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Gabelli downgraded Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Guggenheim began coverage on Zoetis in a report on Thursday, May 23rd. They issued a “buy” rating and a $114.00 target price on the stock. Finally, Credit Suisse Group boosted their target price on Zoetis from $102.00 to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, April 2nd. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $105.00.
TRADEMARK VIOLATION WARNING: This story was originally reported by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://theenterpriseleader.com/2019/06/12/aubrey-capital-management-ltd-grows-position-in-zoetis-inc-nysezts.html.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: Fundamental Analysis
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.